English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Aim: Management of metastatic breast cancer (MBC) remains a great challenge for oncologists. The aim of our study was to evaluate the efficacy and toxicity of capecitabine combined with vinorelbine as a second line treatment in MBC.Materials and Methods: Twenty-three patients with MBC received oral capecitabine (1000 mg/m2/day) for 14 days plus vinorelbine (oral 60 mg/m2 days 1, 8 and 15 or intravenous 25 mg/m2 days 1and 8 according to patients' preference and drug availability).Results: The median age of patients was 52 years and 61% of them were ER –ve / PR-ve and 91% were HER2 –ve. Eighty-three percent of patients failed treatment with anthracyclines and 48% with taxanes. The majority (83%) received the oral formulation of vinorelbine and the median number of cycles per patient was 3. The overall response rate was 56.5%; however, none of the patients achieved complete remission. The median progression free survival for the whole group of patients was 4.2 month. Grade 3- 4 hematological toxicities were more likely to occur with the oral norelbine regimen and there were no treatment-related deaths.Conclusions: Metronomic capecitabine and vinorelbine combination seems to be tolerable and effective as a second line chemotherapy in MBC. A higher dose of capecitabine in combination with vinorelbine, may improve survival and increase the response rate.

Metronomic Capecitabine and Vinorelbine as Second Line Therapy in Advanced Breast Cancer